Kruppel-like factor 8 (KLF8) is a member of the family of KLF transcription factors. Several KLF members have been shown to play a role in oncogenesis. We have previously demonstrated that KLF8 mediates cell cycle progression downstream of focal adhesion kinase (FAK) by upregulating cyclin D1. FAK plays a critical role in transformation and tumorigenesis and is aberrantly upregulated in many types of human cancer. Little is known about the function of KLF8 in these regards. Here we provide evidence suggesting a novel role of KLF8 in oncogenic transformation. We show that KLF8 expression is elevated in several types of human cancer cells and primary tumor tissues. Induced expression of ectopic KLF8 causes serum-independent growth and morphological transformation in NIH3T3 cells and enhances anchorage-independent growth of v-Src-transformed cells. In contrast, expression of a dominant-negative mutant of KLF8 dramatically suppresses the transformed phenotypes induced by v-Src. In addition, the KLF8-enhanced transformation in the v-Src cells was prevented by ablating cyclin D1 expression. Overall, these results indicate that KLF8 is required for v-Src-induced transformation and may play a role in tumor progression of human cancer.
Kruppel-like factor 8 (KLF8) belongs to the family of Kruppel-like transcription factors (van Vliet et al., 2000) . It shares the well-conserved DNA-binding zincfinger domains on its C-terminus. The N-terminal half of KLF8 is thought to determine its functional specificity through recruiting other proteins (Bieker, 2001) . Several members of KLF family proteins, including KLF4 Ghaleb et al., 2005) , KLF5 (Dong, 2001; Chen et al., 2002; Nandan et al., 2004; Ghaleb et al., 2005) , KLF6 Kimmelman et al., 2004; Reeves et al., 2004) and KLF11 (Ellenrieder et al., 2004) , have been implicated to be associated with various types of human cancer. We have previously identified KLF8 as an essential effector downstream of focal adhesion kinase (FAK) for cell cycle regulation by activating cyclin D1 gene promoter (Zhao et al., 2003) . In addition to physiological role in regulating cell proliferation, survival and migration downstream of adhesion receptors and mitogenic receptors (Schlaepfer et al., 1999) , FAK also plays a critical role in oncogenic transformation and tumor progression when deregulated. For example, ectopic expression of constitutively active FAK mutant makes Madin-Darby canine kidney (MDCK) cells capable of anchorage-independent growth and forming tumors in nude mice (Frisch et al., 1996) . Indeed, FAK is overexpressed or functionally hyperactivated in many types of human tumors (Gabarra-Niecko et al., 2003) , including ovarian (Sood et al., 2004; Grisaru-Granovsky et al., 2005) and breast (Cance et al., 2000) carcinomas. Conditional deletion of FAK gene from mouse epidermal keratinocytes prevents carcinogen-induced skin tumor formation (McLean et al., 2004) . Inhibition of FAK in rat mammary adenocarcinoma cells suppresses the cancer cell-derived tumor growth as well as lung metastasis (van Nimwegen et al., 2005) . These results prompted us to study a potential role of KLF8 in malignant transformation.
We first screened various types of human cancer cell lines to determine whether KLF8 expression is deregulated in the cells. Using quantitative real-time polymerase chain reaction and Western analysis, we found that KLF8 is barely expressed in normal human epithelial cells but highly overexpressed in several types of cancer cell lines established from human patients, including ovarian, breast and renal carcinomas (Figure 1a and b) . Consistently, others have demonstrated similar results in the NCI-60 cell lines by cDNA microarray screening (http://smd.stanford.edu/cgi-bin/source/expressionSearch? option ¼ cluster&criteria ¼ Hs.141120&dataset ¼ 2& organism ¼ Hs). Immunofluorescent staining confirmed the nuclear expression of KLF8 in the ovarian cancer cell line SKOV3ip1 (Figure 1c) . Finally, we found that KLF8 is overexpressed in all the human ovarian cancer tissues tested compared to the normal ovarian tissue counterparts in the Human Ovarian Cancer Gene Expression cDNA Panels (OriGene Technologies Inc., Rockville, MD, USA) (Figure 1d ). These results strongly suggest a role for KLF8 in the pathogenesis of human cancer.
To test directly if KLF8 is itself sufficient in mediating oncogenic transformation, we took advantage of our Tet-off NIH3T3 cell lines that express inducible ectopic KLF8 (Zhao et al., 2003) . These cells do not express the ectopic KLF8 if grown in tetracycline-containing medium. Induction of expression of the ectopic KLF8 by removal of tetracycline from the medium led to remarkably accelerated cell growth ( Figure 2A ). The aberrant cell growth was characterized by loss of contact inhibition, overlapping growth ( Figure 2B ) and the less dependence on the serum in the medium ( Figure 2C ). These phenotypes of the cells clearly fit those of fibroblasts transformed by oncoproteins such as v-Src.
Interestingly, we found that induced expression of KLF8 was not sufficient to induce anchorage-independent growth of the cells in soft agar (data not shown). To determine whether or not KLF8 is required for transformation induced by other oncogenes, we first established an inhibitory mutant of KLF8. This mutant lacked the C-terminal one-and-a-half of the DNAbinding zinc-finger motifs owing to the deletion of the last 38 amino acids. We named this mutant as KLF8DC38. As KLF8DC38 maintained the entire Nterminus and remained localized in the nucleus (data not shown), we believed that this mutant possibly acted in a dominant-negative manner by competing with wild-type KLF8 for recruiting other regulatory proteins as described above. We have previously shown that KLF8 promotes cell cycle progression through the G1 phase by activating cyclin D1 promoter (Zhao et al., 2003) . Co-overexpression of KLF8DC38 significantly blocked wild-type KLF8-enhanced cell cycle progression and cyclin D1 promoter activation in a dose-dependent manner, as analysed by 5-bromo-2 0 -deoxy-uridine (BrdU) incorporation assays ( Figure 3A ) and cyclin D1 promoter-driven luciferase reporter assays ( Figure 3B ), respectively. These results confirmed the dominant-negative function of the KLF8DC38 mutant.
We then tested the need for KLF8 in oncogenic transformation by making v-Src-transformed NIH3T3-inducible cell lines that expressed the KLF8DC38 mutant. Similar cell lines that expressed the wild-type KLF8 or empty vector were also generated as essential controls. The expression of the KLF8 proteins were under the control of tetracycline ( Figure 3C ) as described previously (Zhao et al., 2003) . Induction of KLF8DC38 expression led to more than twofold inhibition of both anchorage-dependent growth ( Figure  3D and F) and anchorage-independent growth that was reflected by the decrease in both number and sizes of the colonies formed in the soft agar ( Figure 3E and F). Interestingly, induction of the wild-type KLF8 expression in the v-Src-transformed cells resulted in further increase in both anchorage-dependent growth ( Figure 3D and F) and anchorage-independent growth ( Figure 3E and F) .
We have recently demonstrated that cyclin D1 is a critical transcriptional target and effector of KLF8 in the cell cycle regulation (Zhao et al., 2003; Wei et al., 2006) . Importantly, cyclin D1 has been shown to be essential for v-Src-mediated transformation (Leslie et al., 2006) and we have found that induced expression of the KLF8DC38 mutant in the v-Src cells resulted in a dramatic decrease in the expression of endogenous cyclin D1 (data not shown). We thus tested whether cyclin D1 mediates KLF8-promoted transformation in Taken together, our results show that KLF8 promotes serum-independent growth, loss of contact inhibition, morphological change into spindle-like phenotypes and overlapping cell growth, the hallmark features of oncogenic transformation. Our results also suggest that KLF8 is required for malignant transformation induced by the v-Src oncoprotein and cyclin D1 plays a critical mediating role. Our failure to induce anchorage-independent growth by overexpressing KLF8 alone in HIN3T3 cells could be owing to the use of monoclonal cell lines. We have noticed that for some (A) Overexpression of KLF8DC38 blocks KLF8-promoted cell cycle progression. The pHan-KLF8DC38 plasmid encoding Myc-tagged KLF8DC38 protein was transfected into the NIH3T3 cells expressing inducible KLF8 for 16 h under uninduced conditions. After 24 h serum deprivation, the cells were stimulated with serum with (I) or without (U) KLF8 induction for 12 h before being prepared for BrdU incorporation assays as described previously (Zhao et al., 2000) . (B) Co-expression of KLF8DC38 prevents activation of cyclin D1 promoter by wild-type KLF8. Increased amounts of pHan-KLF8DC38 were co-transfected into NIH3T3 cells with 1 mg of either pKH3 vector or pKH3-KLF8 along with cyclin D1 promoter reporter. Reporter assays were performed as described previously (Zhao et al., 2001) . The protein expression was confirmed by Western blot (data not shown). (C) Induced expression of the HA-tagged KLF8 proteins. V-Src-transformed NIH3T3 cell lines that express inducible HA-KLF8 (KLF8), HA-KLF8DC38 (DC38) or control vector only (mock) were generated as described previously (Zhao et al., 2003) . Western blotting was conducted using anti-HA and whole lysates of cells grown for 72 h under induced (I) and uninduced (U) conditions. (D) KLF8 enhances but its DC38 mutant inhibits growth of v-Src transformed cells. Serum-stimulated growth of the indicated cells was examined as in Figure 2a . (E) KLF8 enhances but its DC38 mutant inhibits anchorage-independent growth of the v-Src transformed cells. Three thousand cells were grown in soft agar for 2 weeks under uninduced (U) and induced (I) conditions. Top media were refreshed twice a week. After 2 weeks, colonies were counted from 10 independent fields and normalized to the uninduced mock cells. (F) The representative phase-contrast pictures of the cells grown on culture dishes for 2 days (a, b, e, f, I, j) and 4 days (c, d, g, h, k, l) or grown in soft agar for 2 weeks (a 0 -f 0 ). The results are representatives for three triplicate experiments.
KLF8 mediates v-Src-induced transformation X Wang and J Zhao unknown reasons, heterogeneous polyclonal cell lines, but not individually cloned cell lines, are more efficient for inducing anchorage-independent growth and tumor formation by oncogenes such as Ras (Lim and Counter, 2004) . Alternatively, KLF8 may be able to induce celltype-specific transformation like FAK, constitutive activation of which is sufficient in the induction of complete malignant transformation of MDCK epithelial cells (Frisch et al., 1996) , but not of fibroblasts (Renshaw et al., 1999) . Our experiments are currently in progress to test this interesting hypothesis as to whether or not KLF8 can fully transform epithelial cells. Another possibility is that KLF8 acts in cooperation with another weak oncogene(s) to regulate transformation. For instance, to transform cells, v-Src needs not only to promote cell proliferation but also to promote adhesion-independent cell survival and to regulate the dynamics of cytoskeleton and cell-cell and cell-matrix adhesions (Frame, 2004) . These multiple requirements by v-Src involve various intermediate signaling proteins with oncogenic potential such as Myc, Akt, STAT and Rho family proteins. It will be intriguing to investigate how KLF8 cooperates with these proteins in oncogenic transformation. As FAK signaling has also been demonstrated to play a key role in cell invasion (Schlaepfer and Mitra, 2004) and tumor metastasis (Benlimame et al., 2005; van Nimwegen et al., 2005) , it will be interesting to test whether KLF8 also plays such roles. In summary, our studies described here clearly establish a novel role for KLF8 in regulating oncogenic transformation. Our finding that KLF8 is overexpressed in human cancer (Figure 1) , combined with considerable evidence that link elevated expression and/or activity of Src, FAK and cyclin D1 with the development of human cancer (Diehl, 2002; Gabarra-Niecko et al., 2003; Summy and Gallick, 2003) , strongly suggests a potentially significant role for KLF8 in tumor progression of human cancer.
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